Table 2.

Proteasomal inhibitors in renal diseases

Proteasome inhibitors	Disease	Model	Function	Reference
Zetomipzomib (KZR-616)	Lupus nephritis	Lupus nephritis mouse model	Reduce proteinuria and anti-dsDNA antibodies	72
Bortezomib	Lupus nephritis	2014-2020 SLE patients treated with Bortezomib at Swedish University Hospitals	Reduce proteinuria and seroconversion of antibodies	73
Bortezomib	Kidney transplantation	Non-human primate kidney transplantation model	Reduce antibody-mediated rejection	74
Carfilzomib (PR-171)	Kidney transplantation	Nonhuman primate kidney transplantation model	Reduce serum donor-specific antibody levels and improve kidney graft function	75
Carfilzomib (PR-171)	Kidney transplantation	Thirteen highly sensitized kidney transplant candidates at the Christ Hospital and the University of Cincinnati, in Cincinnati, OH	Deplete of plasma cells and reduce HLA antibodies	76
Ixazomib	Kidney transplantation	Phase II clinical trial of highly sensitized renal transplant candidates	May induce renal graft desensitization	77
Marizomib	Hereditary leiomyomatosis and renal cell carcinoma	UOK262-induced renal tumor mice model	Inhibit the metabolism of glutamine and glucose	78
MG132	Diabetic kidney disease	STZ-induced diabetic mouse models	Inhibit renal inflammation, mesangial cell proliferation, and renal fibrosis	79
MG132	Diabetic kidney disease	STZ-induced diabetic mouse models	Inhibit oxidative damage and inflammatory responses in the kidney	80
PSI	Diabetic kidney disease	STZ-induced diabetic mouse models	Inhibit NF-κB signaling pathways	81
Delanzomib	Renal fibrosis	Unilateral ureteric obstruction mouse model	Induce myofibroblast death	83